ConductScience.org, home

Paper17548498

Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.

Nakata H and 11 others. Antimicrob Agents Chemother, 2007. Cited by 86 papers, by iCite.

Cite this record

ConductScience Library. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine. Papers, record 17548498. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17548498

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
2007
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
86
iCite
Relative citation ratio, by iCite
2.06
iCite
Revised in PubMed
2022-03-16
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Nakata HHirotomo
2Amano MMasayuki
3Koh YYasuhiro
4Kodama EEiichi
5Yang GGuangwei
6Bailey CMChristopher M
7Kohgo SSatoru
8Hayakawa HHiroyuki
9Matsuoka MMasao
10Anderson KSKaren S
11Cheng YCYung-Chi
12Mitsuya HHiroaki

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-HIV AgentsMajor topic
DNA-Directed DNA PolymeraseMajor topic
DeoxyadenosinesMajor topic
HIV-1Major topic
Reverse Transcriptase InhibitorsMajor topic
CD4-Positive T-Lymphocytes
Cells, Cultured
Culture Media
Humans
Microbial Sensitivity Tests
Tritium
Zidovudine

Source PubMed

Download CSV of topics

Grants7

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 AI038204NIAID NIH HHSUnited StatesR01AI038204PubMed and NIHNIH RePORTER
R56 AI038204NIAID NIH HHSUnited StatesR01AI038204PubMed and NIHNIH RePORTER
Intramural NIH HHSUnited StatesPubMedPubMed
R01 GM049551NIGMS NIH HHSUnited StatesR01GM049551PubMed and NIHNIH RePORTER
AI38204NIAID NIH HHSUnited StatesR01AI038204PubMed and NIHNIH RePORTER
GM49551NIGMS NIH HHSUnited StatesR01GM049551PubMed and NIHNIH RePORTER
Z01SC006738NIHNIH RePORTER

Download CSV of grants

References27

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110570065Intracellular metabolism of CycloSaligenyl 3'-azido-2', 3'-dideoxythymidine monophosphate, a prodrug of 3'-azido-2', 3'-dideoxythymidine (zidovudine).Mol Pharmacol1999https://conductscience.org/library/papers/10570065PubMed
217371811A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.Antimicrob Agents Chemother2007https://conductscience.org/library/papers/17371811PubMed
3113028244'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.Antimicrob Agents Chemother2001https://conductscience.org/library/papers/11302824PubMed
411454872Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.J Biol Chem2001https://conductscience.org/library/papers/11454872PubMed
511594679The molecular basis of inhibition and toxicity of modified cytosine analogues targetting HIV-1 reverse transcriptase.Antivir Chem Chemother2001https://conductscience.org/library/papers/11594679PubMed
611692304Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases.Clin Infect Dis2001https://conductscience.org/library/papers/11692304PubMed
711773409A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.J Virol2002https://conductscience.org/library/papers/11773409PubMed
812119605Strategies in the design of antiviral drugs.Nat Rev Drug Discov2002https://conductscience.org/library/papers/12119605PubMed
9124552294'-C-substituted-2'-deoxynucleosides: a family of antiretroviral agents which are potent against drug-resistant HIV variants.Curr Drug Targets Infect Disord2001https://conductscience.org/library/papers/12455229PubMed
1014506019Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.Antimicrob Agents Chemother2003https://conductscience.org/library/papers/14506019PubMed
1115035022HIV-1 dynamics in vivo: implications for therapy.Nat Rev Microbiol2003https://conductscience.org/library/papers/15035022PubMed
1215199316HIV-associated neuromuscular weakness syndrome.AIDS2004https://conductscience.org/library/papers/15199316PubMed
1315163657A long-term latent reservoir for HIV-1: discovery and clinical implications.J Antimicrob Chemother2004https://conductscience.org/library/papers/15163657PubMed
1415238771SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.AIDS2004https://conductscience.org/library/papers/15238771PubMed
1515456247A 4'-C-ethynyl-2',3'-dideoxynucleoside analogue highlights the role of the 3'-OH in anti-HIV active 4'-C-ethynyl-2'-deoxy nucleosides.J Med Chem2004https://conductscience.org/library/papers/15456247PubMed
162430286Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.Proc Natl Acad Sci U S A1986https://conductscience.org/library/papers/2430286PubMed
1721091832'-Fluoro-2',3'-dideoxyarabinosyladenine: a metabolically stable analogue of the antiretroviral agent 2',3'-dideoxyadenosine.Mol Pharmacol1990https://conductscience.org/library/papers/2109183PubMed
181730594Metabolism of 4'-azidothymidine. A compound with potent and selective activity against the human immunodeficiency virus.J Biol Chem1992https://conductscience.org/library/papers/1730594PubMed
198387546Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.J Clin Invest1993https://conductscience.org/library/papers/8387546PubMed
207685186Selective action of 4'-azidothymidine triphosphate on reverse transcriptase of human immunodeficiency virus type 1 and human DNA polymerases alpha and beta.Biochemistry1993https://conductscience.org/library/papers/7685186PubMed

See all 27 referencesDownload CSV of references

Cited by62

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 86 citations.

PMIDTitleJournalYearIn PapersSource
40042304Pharmacokinetics of islatravir in participants with moderate hepatic impairment.Antimicrob Agents Chemother2025https://conductscience.org/library/papers/40042304PubMed
39831159An orally available P1'-5-fluorinated Mpro inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier.PNAS Nexus2025https://conductscience.org/library/papers/39831159PubMed
39105584Intracellular islatravir-triphosphate half-life supports extended dosing intervals.Antimicrob Agents Chemother2024https://conductscience.org/library/papers/39105584PubMed
36933835A novel anti-HBV agent, E-CFCP, restores Hepatitis B virus (HBV)-induced senescence-associated cellular marker perturbation in human hepatocytes.Virus Res2023https://conductscience.org/library/papers/36933835PubMed
36841831Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2.Nat Commun2023https://conductscience.org/library/papers/36841831PubMed
36346229Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency.Antimicrob Agents Chemother2022https://conductscience.org/library/papers/36346229PubMed
35847492Approved HIV reverse transcriptase inhibitors in the past decade.Acta Pharm Sin B2022https://conductscience.org/library/papers/35847492PubMed
35475215A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro.Cell Rep Methods2021https://conductscience.org/library/papers/35475215PubMed
34676683Lack of a Clinically Meaningful Drug Interaction Between the HIV-1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate.Clin Pharmacol Drug Dev2021https://conductscience.org/library/papers/34676683PubMed
34516245Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains.Antimicrob Agents Chemother2021https://conductscience.org/library/papers/34516245PubMed
34463432Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIV.Clin Transl Sci2021https://conductscience.org/library/papers/34463432PubMed
33333207Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.J Hepatol2021https://conductscience.org/library/papers/33333207PubMed
32737197Mechanistic cross-talk between DNA/RNA polymerase enzyme kinetics and nucleotide substrate availability in cells: Implications for polymerase inhibitor discovery.J Biol Chem2020https://conductscience.org/library/papers/32737197PubMed
320845067-Deaza-7-fluoro modification confers on 4'-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety.Antiviral Res2020https://conductscience.org/library/papers/32084506PubMed
32080249Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.Sci Rep2020https://conductscience.org/library/papers/32080249PubMed
31992748Potent inhibition of HIV replication in primary human cells by novel synthetic polyketides inspired by Aureothin.Sci Rep2020https://conductscience.org/library/papers/31992748PubMed
31774001Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States.Expert Rev Clin Pharmacol2019https://conductscience.org/library/papers/31774001PubMed
31424371Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication.Curr Top Med Chem2019https://conductscience.org/library/papers/31424371PubMed
31085520
Novel Protease Inhibitors Containing C-5-Modified bis-Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2' Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance.
Antimicrob Agents Chemother2019https://conductscience.org/library/papers/31085520PubMed
30670420CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.Antimicrob Agents Chemother2019https://conductscience.org/library/papers/30670420PubMed

See all 62 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17548498

GET https://conductscience.org/api/papers/v1/17548498/references?page=2